Viking Therapeutics Falls 2.84% as S&P 500 Also Slips
The biotech stock lagged the broader market at the latest close, while Zacks estimates a $1-per-share loss in upcoming results.
Key takeaways
- Viking Therapeutics fell 2.84% to $27.73 at the latest close.
- Zacks projects upcoming earnings of -$1 per share.
Viking Therapeutics fell 2.84% to $27.73 at the latest close, while the S&P 500 lost 0.47%. The Dow rose 0.1%, and the Nasdaq fell 1.25%.
Over the previous month, the shares dropped 12.72%, compared with a 3.97% decline in the Medical sector and a 1.15% gain for the S&P 500.
Ahead of the company’s upcoming earnings release, Zacks estimates earnings of -$1 per share, a year-over-year decline of 23.46%. For the annual period, Zacks Consensus Estimates project earnings of -$4.47 per share and revenue of $0 million. The consensus earnings-per-share estimate has not changed over the past month, Zacks said.
This article was produced with the help of AI technology. Source: Yahoo Finance
